FY2028 Earnings Estimate for AXSM Issued By Leerink Partnrs

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Stock analysts at Leerink Partnrs decreased their FY2028 earnings estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Tuesday, February 18th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings of $9.70 per share for the year, down from their prior estimate of $9.90. The consensus estimate for Axsome Therapeutics' current full-year earnings is ($2.26) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics' FY2029 earnings at $16.85 EPS.

A number of other brokerages also recently issued reports on AXSM. Robert W. Baird boosted their price objective on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the company an "outperform" rating in a research report on Wednesday, November 13th. Truist Financial boosted their price target on Axsome Therapeutics from $190.00 to $200.00 and gave the company a "buy" rating in a report on Wednesday. Wells Fargo & Company raised their price objective on Axsome Therapeutics from $140.00 to $160.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. Mizuho lifted their price objective on Axsome Therapeutics from $137.00 to $195.00 and gave the company an "outperform" rating in a research report on Tuesday, February 11th. Finally, Deutsche Bank Aktiengesellschaft began coverage on shares of Axsome Therapeutics in a report on Tuesday, February 11th. They issued a "buy" rating and a $176.00 target price for the company. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Axsome Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $155.47.

Axsome Therapeutics Stock Performance

NASDAQ AXSM traded up $8.65 during trading hours on Thursday, hitting $137.75. 1,539,189 shares of the company's stock traded hands, compared to its average volume of 1,103,887. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $139.13. The firm has a market capitalization of $6.72 billion, a P/E ratio of -23.00 and a beta of 1.05. The company has a current ratio of 2.11, a quick ratio of 2.37 and a debt-to-equity ratio of 3.22. The business's fifty day moving average price is $101.29 and its two-hundred day moving average price is $94.84.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last announced its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The business had revenue of $118.77 million for the quarter, compared to analysts' expectations of $117.83 million.

Insider Buying and Selling at Axsome Therapeutics

In related news, CFO Nick Pizzie sold 3,000 shares of the business's stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 22.40% of the company's stock.

Hedge Funds Weigh In On Axsome Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Raiffeisen Bank International AG purchased a new position in Axsome Therapeutics in the fourth quarter worth about $51,000. Assetmark Inc. purchased a new position in shares of Axsome Therapeutics in the 4th quarter worth approximately $52,000. R Squared Ltd purchased a new position in shares of Axsome Therapeutics in the 4th quarter worth approximately $64,000. Aquatic Capital Management LLC bought a new position in shares of Axsome Therapeutics during the 4th quarter valued at approximately $76,000. Finally, GF Fund Management CO. LTD. purchased a new stake in Axsome Therapeutics during the 4th quarter valued at $86,000. Hedge funds and other institutional investors own 81.49% of the company's stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.